BioStock: Curasight expands its clinical portfolio

Several investigator-initiated trials have lately shown great results for Curasight’s PET tracer uTRACE, strengthening the company´s uPAR approach to cancer diagnostics. Following the positive results seen in neuroendocrine tumours and head and neck cancer, the Danish biotech has decided to expand its clinical portfolio with the two indications. BioStock has contacted CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/curasight-expands-its-clinical-portfolio/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se